Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ImmunityBio, Inc.IBRX · Entity 3618 | Director | July 01, 2026 | July 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ImmunityBio, Inc.
Report date July 01, 2026 · Filed July 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-07-01 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-07-01 · Exercise / conversion · Acquired 35,064 · Balance 35,064 Row 2 · 2026-07-01 · Exercise / conversion · Acquired 124,414 · Balance 159,478 Row 3 · 2026-07-01 · Sale · Disposed 159,478 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026. F2: Represents the weighted average share price of an aggregate total of 159,478 shares sold in the price range of $9.00 to $9.07 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.98 · Expires 2032-06-14 | Direct | 0 |
Reported balance
After 2026-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-01 · Exercise / conversion · Disposed 35,064 · Balance 0 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.99 · Expires 2033-06-13 | Direct | 0 |
Reported balance
After 2026-07-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-01 · Exercise / conversion · Disposed 124,414 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026.
F2: Represents the weighted average share price of an aggregate total of 159,478 shares sold in the price range of $9.00 to $9.07 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 7, 2026 00:25 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 124,414 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0001849739-26-000014 · wk-form4_1783383927.xml · derivative · entry 5 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 124,414 shares Expires 2033-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2026 Filed Jul 7, 2026 00:25 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 35,064 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001849739-26-000014 · wk-form4_1783383927.xml · derivative · entry 4 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,064 shares Expires 2032-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2026 Filed Jul 7, 2026 00:25 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | SaleCommon Stock | 159,478 | $9.02 | $1,439,065.68 |
DisclosureSEC source: 0001849739-26-000014 · wk-form4_1783383927.xml · nonDerivative · entry 3 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026. F2 · price: Represents the weighted average share price of an aggregate total of 159,478 shares sold in the price range of $9.00 to $9.07 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 01, 2026 Filed Jul 7, 2026 00:25 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 124,414 | $2.99 | $371,997.86 |
DisclosureSEC source: 0001849739-26-000014 · wk-form4_1783383927.xml · nonDerivative · entry 2 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 159,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2026 Filed Jul 7, 2026 00:25 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 35,064 | $2.98 | $104,490.72 |
DisclosureSEC source: 0001849739-26-000014 · wk-form4_1783383927.xml · nonDerivative · entry 1 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 21:04 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 300 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · derivative · entry 12 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,414 Underlying: Common Stock · 300 shares Expires 2033-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 21:04 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 700 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · derivative · entry 11 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,064 Underlying: Common Stock · 700 shares Expires 2032-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 21:04 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | SaleCommon Stock | 1,000 | $9.00 | $9,000.00 |
DisclosureSEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · nonDerivative · entry 7 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 21:04 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 300 | $2.99 | $897.00 |
DisclosureSEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · nonDerivative · entry 6 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2026 Filed Jul 1, 2026 21:04 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 700 | $2.98 | $2,086.00 |
DisclosureSEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · nonDerivative · entry 5 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 21:04 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · derivative · entry 10 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,786 Underlying: Common Stock · 30,000 shares Expires 2035-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 21:04 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 33,549 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · derivative · entry 9 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,714 Underlying: Common Stock · 33,549 shares Expires 2033-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 21:04 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 32,173 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · derivative · entry 8 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,764 Underlying: Common Stock · 32,173 shares Expires 2032-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 21:04 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | SaleCommon Stock | 95,722 | $9.01 | $862,215.92 |
DisclosureSEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · nonDerivative · entry 4 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 13, 2026. F2 · price: Represents the weighted average share price of an aggregate total of 95,722 shares sold in the price range of $9.00 to $9.08 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, ImmunityBio, Inc. (the "Issuer") or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 21:04 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 30,000 | $2.84 | $85,200.00 |
DisclosureSEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · nonDerivative · entry 3 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 21:04 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 33,549 | $2.99 | $100,311.51 |
DisclosureSEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · nonDerivative · entry 2 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2026 Filed Jul 1, 2026 21:04 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 32,173 | $2.98 | $95,875.54 |
DisclosureSEC source: 0001849739-26-000011 · wk-form4_1782939871.xml · nonDerivative · entry 1 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2026 Filed Jun 11, 2026 00:11 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 65,600 | $0.00 Strike: $7.25 | $0.00 |
DisclosureSEC source: 0001849739-26-000007 · wk-form4_1781136666.xml · derivative · entry 1 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,600 Underlying: Common Stock · 65,600 shares Expires 2036-06-09 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 01:05 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001849739-26-000004 · wk-form4_1771981555.xml · derivative · entry 3 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 67,937 Underlying: Common Stock · 25,000 shares Expires 2032-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the award vested on June 12, 2023, the date immediately preceding the 2023 annual meeting of stockholders. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 01:05 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | SaleCommon Stock | 25,000 | $10.00 | $250,000.00 |
DisclosureSEC source: 0001849739-26-000004 · wk-form4_1771981555.xml · nonDerivative · entry 2 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 01:05 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 25,000 | $2.98 | $74,500.00 |
DisclosureSEC source: 0001849739-26-000004 · wk-form4_1771981555.xml · nonDerivative · entry 1 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 01:33 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001849739-26-000002 · wk-form4_1769045624.xml · derivative · entry 6 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,937 Underlying: Common Stock · 25,000 shares Expires 2032-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the award vested on June 12, 2023, the date immediately preceding the 2023 annual meeting of stockholders. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 01:33 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | SaleCommon Stock | 25,000 | $7.51 | $187,650.00 |
DisclosureSEC source: 0001849739-26-000002 · wk-form4_1769045624.xml · nonDerivative · entry 4 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025. F2 · price: Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $7.50 to $7.52 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 01:33 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 25,000 | $2.98 | $74,500.00 |
DisclosureSEC source: 0001849739-26-000002 · wk-form4_1769045624.xml · nonDerivative · entry 3 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 16, 2026 Filed Jan 22, 2026 01:33 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001849739-26-000002 · wk-form4_1769045624.xml · derivative · entry 5 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,937 Underlying: Common Stock · 50,000 shares Expires 2032-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the award vested on June 12, 2023, the date immediately preceding the 2023 annual meeting of stockholders. Read SEC document |
| January 16, 2026 Filed Jan 22, 2026 01:33 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | SaleCommon Stock | 50,000 | $5.00 | $250,000.00 |
DisclosureSEC source: 0001849739-26-000002 · wk-form4_1769045624.xml · nonDerivative · entry 2 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025. Read SEC document |
| January 16, 2026 Filed Jan 22, 2026 01:33 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | Exercise / conversionCommon Stock | 50,000 | $2.98 | $149,000.00 |
DisclosureSEC source: 0001849739-26-000002 · wk-form4_1769045624.xml · nonDerivative · entry 1 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 22:34 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 162,786 | $0.00 Strike: $2.84 | $0.00 |
DisclosureSEC source: 0001326110-25-000094 · wk-form4_1750458891.xml · derivative · entry 1 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,786 Underlying: Common Stock · 162,786 shares Expires 2035-06-18 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 18, 2026 or the date immediately preceding the Issuer's next annual meeting of stockholders. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 22:49 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 77,633 | $0.00 Strike: $5.96 | $0.00 |
DisclosureSEC source: 0001326110-24-000078 · wk-form4_1718318961.xml · derivative · entry 1 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,633 Underlying: Common Stock · 77,633 shares Expires 2034-06-11 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 11, 2025 or the date immediately preceding the next annual meeting of stockholders. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:30 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 158,263 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0001326110-23-000090 · wk-form4_1686868200.xml · derivative · entry 1 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,263 Underlying: Common Stock · 158,263 shares Expires 2033-06-13 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 13, 2024 or the date immediately preceding the next annual meeting of stockholders. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 01:26 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 167,937 | $0.00 Strike: $2.98 | $0.00 |
DisclosureSEC source: 0001326110-22-000052 · wf-form4_165534277881126.xml · derivative · entry 1 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,937 Underlying: Common Stock · 167,937 shares Expires 2032-06-14 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 14, 2023 or the date immediately preceding the 2023 annual meeting of stockholders. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 22:36 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 26,064 | $0.00 Strike: $14.91 | $0.00 |
DisclosureSEC source: 0001209191-21-040354 · doc4.xml · derivative · entry 1 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,064 Underlying: Common Stock · 26,064 shares Expires 2031-06-10 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 10, 2022 or the date immediately preceding the 2022 annual meeting of stockholders. Read SEC document |
| May 03, 2021 Filed May 5, 2021 22:06 UTC | ImmunityBio, Inc. IBRX · Entity 3618 | GrantStock Option (right to buy) · Derivative | 21,873 | $0.00 Strike: $17.24 | $0.00 |
DisclosureSEC source: 0001209191-21-030448 · doc4.xml · derivative · entry 1 Selecky Christobel · CIK 0001849739 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,873 Underlying: Common Stock · 21,873 shares Expires 2031-05-03 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2015 Equity Incentive Plan) through such applicable vesting date, the shares subject to the award will vest in three (3) equal installments on each of March 9, 2022, March 9, 2023 and March 9, 2024, such that the award will be fully vested March 9, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.